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South Africa is currently experiencing a TB epidemic with 
an estimated incidence of 940/100 000 population/year, and 
the country has been ranked 4th among the 22 high-burden 
TB countries worldwide by the World Health Organization 
(WHO).1 A potentially devastating threat to TB control is the 
emergence of multidrug-resistant TB (MDR-TB) and, more 
recently, extensively drug-resistant TB (XDR-TB), mainly as 
a result of poor drug adherence by TB patients and incorrect 
management or treatment regimens by health providers; 
however, direct transmission of drug-resistant strains also 
plays an important role. The MDR/XDR-TB strains necessitate 
prolonged chemotherapy for up to 2 years or more, and the use 
of more toxic second-line drugs including the aminoglycoside 
(streptomycin, kanamycin and amikacin) and polypeptide 
(capreomycin) antibiotics. In South Africa, in accordance with 
WHO guidelines, streptomycin is used for retreatment of TB 
while kanamycin, amikacin and capreomycin are used to treat 
MDR/XDR-TB.2
Although effective for treating MDR-TB, the aminoglycosides 
and capreomycin have known dose-related adverse effects, 
mainly nephrotoxicity and ototoxicity (defined as damage 
to the hearing or balance functions of the ear). Fortunately, 
the renal impairment is usually reversible. The ototoxicity, 
however, is permanent and is due to the death of the outer hair 
cells in the organ of Corti of the cochlea and type I sensory 
cells in the vestibular organ (MIM 580000).3 Aminoglycosides 
are known to persist in the inner ear tissues for 6 months or 
longer after administration. These drugs appear to generate 
free radicals within the inner ear that trigger apoptotic and 
necrotic cell death of sensory cells and neurons.4 Streptomycin 
produces predominantly vestibular damage, while kanamycin 
and amikacin mainly affect the cochlea.3 Despite their adverse 
effects, aminoglycosides are commonly used as short-course 
antibiotics in developing countries such as South Africa and 
are, together with capreomycin, important components of the 
MDR-/XDR-TB drug regimens for 6 months or longer. South 
Africa is therefore potentially facing the risk of a significant 
proportion of the population acquiring aminoglycoside-
induced permanent hearing loss. Aminoglycoside-induced 
hearing loss has a major impact on the ability of affected 
individuals to secure jobs and, since the majority of TB patients 
are from poor socio-economic backgrounds, there will be 
increased demands on the country’s social welfare and health 
care budgets.
Risk factors
Risk factors for aminoglycoside ototoxicity include therapy 
lasting >7 days, prior exposure to aminoglycosides, high 
daily doses, elevated serum levels, noise exposure, use in 
the very young or very elderly, and the presence of specific 
mitochondrial DNA mutations.5 There are at least 6 mutations 
described to date (A1555G, T1095C, C1494T, A827G, 961delT 
and T1291C).6 The A1555G mutation has been described in 
numerous populations worldwide, including Chinese, Spanish 
and Arab-Israeli (MIM 561000). This mutation has also been 
found in a South African family in which 11 family members 
were diagnosed with aminoglycoside-induced hearing loss 
following streptomycin treatment for TB.7 In subsequent 
generations of this large family, several of the children will also 
be at risk of developing aminoglycoside-induced hearing loss. 
Since these are mitochondrial DNA mutations, all maternal 
relatives harbour the mutation, and mutation-positive mothers 
will transmit the mutation to all of their children. Besides 
this one reported South African family, there are potentially 
many other families that have one of the known mitochondrial 
mutations.
It is important to determine the frequency of these mutations 
in the general South African population to determine what 
percentage of our population is at risk and to assist health 
care planners. All TB patients should ideally be tested before 
they start aminoglycoside therapy to determine whether 
they harbour any of the known aminoglycoside ototoxicity-
associated mutations. Patients at risk of aminoglycoside 
ototoxicity can then be prioritised for regular audiological 
monitoring during the course of their treatment; this would 
lead to more efficient use of South Africa’s very limited 
audiology facilities. Furthermore, if patients are known to have 
an ototoxicity-associated mutation, early recognition of disease 
and early treatment is important i.e. to do drug-susceptibility 
testing immediately that TB is diagnosed, even if it is the first 
TB episode, and not to wait until patients do not respond to 
treatment and more extensive disease is present. This could 
lead to shorter courses of treatment with the second-line 
injectable agents. A further option not generally considered 
would be to give preventive treatment to those newly infected 
with MDR-TB strains, especially children and HIV-infected 
patients of any age, by giving a combination of two drugs 
to which the source case is susceptible or naïve for a period 
of 6 - 9 months, to prevent them from developing MDR-TB 
(American Thoracic Society/Centers for Disease Control and 
Prevention (ATS/CDC) guideline – not WHO).8
We have developed a cost-effective genetic screening test, 
based on the SNaPshot technique (Applied Biosystems, 
Foster City, USA), which can determine the presence of six of 
the known mitochondrial mutations in a single reaction.9 It 
should be noted, however, that these six mutations have been 
identified in overseas – particularly Asian – populations, and it 
is therefore likely that the South African population has novel 
mutations owing to our unique ancestral origins. In the future, 
once ‘local’ mutations have been identified, they should be 
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added to the panel of mutations screened for by the genetic 
screening test.
Minimising hearing loss
Even though aminoglycosides or polypeptide antibiotics cannot 
be discontinued in mutation-positive individuals diagnosed 
with MDR- or XDR-TB, the following strategies can be 
adopted to minimise the extent of hearing loss in such patients: 
reduction in therapy time, establishing an evidence-based 
audiological monitoring protocol, avoidance of excessive noise 
exposure, avoidance of drugs with synergistic ototoxic effects 
(e.g. loop diuretics, antimalarials), and the use of antioxidants. 
A double-blind randomised study of 195 patients demonstrated 
that administration of the antioxidant aspirin for 14 days 
protected against development of gentamicin-induced hearing 
loss.10 This should be further investigated in TB patients 
receiving long-term aminoglycoside or polypeptide therapy. 
Family members of mutation-positive individuals should also 
be counselled about their risk of developing aminoglycoside-
induced hearing loss.
In conclusion: until affordable, less toxic drugs for resistant 
forms of TB have been developed, we should take cognisance 
of the fact that the global TB epidemic has also led to an 
increased burden of aminoglycoside-induced hearing loss, with 
its economic and social consequences. South Africa needs to 
take immediate and effective steps to preserve hearing in the 
thousands of individuals on TB treatment. Introducing genetic 
testing for patients at risk of aminoglycoside-induced hearing 
loss should be strongly considered as part of such a strategy.
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